What is DNAnexus?
DNAnexus operates as a leading bioinformatics platform, providing an end-to-end integrated environment for diagnostic R&D and production-scale data analysis. By bridging the gap between raw biomedical data and actionable scientific insights, the company supports a diverse array of stakeholders, including national biobanks and pharmaceutical giants. Its multi-omics data science platform is engineered to accelerate target drug discovery and enhance patient care outcomes through secure, collaborative workflows. Positioned at the intersection of technology and biology, DNAnexus enables organizations to navigate the complexities of genomic information at scale, effectively transforming how the healthcare industry leverages data for precision medicine.
How much funding has DNAnexus raised?
DNAnexus has raised a total of $472.6M across 8 funding rounds:
Series B
$15M
Series C
$15M
Series D
$15M
Series E
$58M
Series F
$68M
Series G
$100M
Unspecified
$200M
Series B (2011): $15M led by Felicis Ventures, First Round Capital, SoftTech VC, Google Ventures, K9 Ventures, and TPG Biotech
Series C (2013): $15M supported by TPG Biotech, Claremont Creek Ventures, First Round Capital, and Google Ventures
Series D (2015): $15M featuring WuXi AppTec
Series E (2018): $58M backed by WuXi NextCODE, Google Ventures, Microsoft, MidCap Financial, TPG Biotech, Claremont Creek Ventures, and Foresite Capital
Series F (2019): $68M with participation from WuXi NextCODE, GV, Innovatus Capital Partners, Foresite Capital, Claremont Creek Ventures, and TPG Biotech
Series G (2020): $100M led by First Round Capital, Foresite Capital, Perceptive Advisors LLC, Texas Pacific Group, Regeneron Pharmaceuticals , Inc., Google Ventures, and Northpond Ventures LLC
Unspecified (2022): $200M supported by Innovatus Capital Partners, Perceptive Advisors, GV, Foresite Capital, Blackstone Accelerates Growth, and Northpond Ventures
Key Investors in DNAnexus
Google Ventures
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data.
TPG Biotech
TPG is a global alternative asset management firm with investment strategies spanning private equity and growth equity, managing capital to drive long-term value creation in healthcare.
What's next for DNAnexus?
With the support of its latest strategic financing, DNAnexus is well-positioned to deepen its penetration into the global life sciences market. The company is expected to prioritize the expansion of its cloud-based infrastructure to accommodate the increasing demand for high-throughput genomic processing and multi-omics integration. By leveraging its strong relationships with institutional investors, DNAnexus will likely focus on scaling its enterprise solutions to support larger, more complex national-level biomedical initiatives. As the industry shifts toward data-driven drug discovery, the company's focus will remain on maintaining its competitive edge through continuous platform innovation and the strengthening of its collaborative ecosystem, ensuring it remains the backbone for organizations seeking to unlock the full potential of biomedical research.
See full DNAnexus company page
